Jon Faiz Kayyem insider trades: Inhibrx Biosciences (INBX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jon reports to the SEC
Open-market buys and sales
88 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | INBX | ↑ Buy | 5,000 | $100.00 | $500K | By The Jon F. Kayyem and Paige Gates-Kay | Sep 23, 2026 (0d) |
| Sep 16, 2026 | INBX | ↑ Buy | 5,000 | $100.00 | $500K | By The Jon F. Kayyem and Paige Gates-Kay | Sep 17, 2026 (1d) |
| Sep 8, 2026 | INBX | ↑ Buy | 5,000 | $113.52 | $568K | By The Jon F. Kayyem and Paige Gates-Kay | Sep 8, 2026 (0d) |
| Nov 20, 2024 | INBX | ↑ Buy | 53,593 | $14.21 | $762K | By Child A | Nov 22, 2024 (2d) |
| Nov 20, 2024 | INBX | ↑ Buy | 53,593 | $14.21 | $762K | By Child B | Nov 22, 2024 (2d) |
| Jun 5, 2024 | INBX | ↑ Buy | 57,549 | $17.32 | $997K | By The Jon F. Kayyem and Paige Gates-Kay | Jun 7, 2024 (2d) |
| Jun 4, 2024 | INBX | ↑ Buy | 286,786 | $17.18 | $4.9M | By The Jon F. Kayyem and Paige Gates-Kay | Jun 4, 2024 (0d) |
| Jan 23, 2023 | INBX | ↓ Sell | 9,500 | $25.26 | $240K | By The Jon F. Kayyem and Paige Gates-Kay | Jan 23, 2023 (0d) |
| Dec 21, 2022 | INBX | ↓ Sell | 9,500 | $27.02 | $257K | By The Jon F. Kayyem and Paige Gates-Kay | Dec 22, 2022 (1d) |
| Nov 21, 2022 | INBX | ↓ Sell | 9,500 | $29.89 | $284K | By The Jon F. Kayyem and Paige Gates-Kay | Nov 22, 2022 (1d) |
| Nov 21, 2022 | BDSX | ↑ Buy | 173,913 | $1.15 | $200K | By The Jon Faiz Kayyem Revocable Trust | Nov 21, 2022 (0d) |
| Oct 21, 2022 | INBX | ↓ Sell | 9,500 | $30.13 | $286K | By The Jon F. Kayyem and Paige Gates-Kay | Oct 24, 2022 (3d) |
| Feb 2, 2018 | GNMK | ↓ Sell | 148 | $5.13 | $759 | Direct | Feb 6, 2018 (4d) |
| Dec 4, 2017 | GNMK | ↓ Sell | 135 | $4.70 | $635 | Direct | Dec 6, 2017 (2d) |
| Nov 20, 2017 | GNMK | ↓ Sell | 1,269 | $4.74 | $6K | Direct | Nov 21, 2017 (1d) |
| Nov 2, 2017 | GNMK | ↓ Sell | 135 | $7.24 | $977 | Direct | Nov 3, 2017 (1d) |
| Sep 5, 2017 | GNMK | ↓ Sell | 133 | $9.75 | $1K | Direct | Sep 6, 2017 (1d) |
| Aug 21, 2017 | GNMK | ↓ Sell | 1,277 | $9.45 | $12K | Direct | Aug 23, 2017 (2d) |
| Aug 2, 2017 | GNMK | ↓ Sell | 138 | $10.33 | $1K | Direct | Aug 4, 2017 (2d) |
| Jun 2, 2017 | GNMK | ↓ Sell | 132 | $12.89 | $2K | Direct | Jun 5, 2017 (3d) |
| May 19, 2017 | GNMK | ↓ Sell | 1,265 | $12.89 | $16K | Direct | May 23, 2017 (4d) |
| May 2, 2017 | GNMK | ↓ Sell | 133 | $13.34 | $2K | Direct | May 4, 2017 (2d) |
| Mar 7, 2017 | GNMK | ↓ Sell | 311 | $12.18 | $4K | Direct | Mar 9, 2017 (2d) |
| Mar 3, 2017 | GNMK | ↓ Sell | 131 | $12.29 | $2K | Direct | Mar 3, 2017 (0d) |
| Feb 21, 2017 | GNMK | ↓ Sell | 5,250 | $10.08 | $53K | Direct | Feb 21, 2017 (0d) |
| Feb 2, 2017 | GNMK | ↓ Sell | 131 | $11.58 | $2K | Direct | Feb 3, 2017 (1d) |
| Jan 19, 2017 | GNMK | ↓ Sell | 5,718 | $12.47 | $71K | Direct | Jan 20, 2017 (1d) |
| Dec 7, 2016 | GNMK | ↓ Sell | 313 | $11.08 | $3K | Direct | Dec 9, 2016 (2d) |
| Dec 2, 2016 | GNMK | ↓ Sell | 132 | $11.30 | $1K | Direct | Dec 6, 2016 (4d) |
| Nov 2, 2016 | GNMK | ↓ Sell | 135 | $10.30 | $1K | Direct | Nov 4, 2016 (2d) |
| Sep 7, 2016 | GNMK | ↓ Sell | 310 | $8.69 | $3K | Direct | Sep 9, 2016 (2d) |
| Sep 2, 2016 | GNMK | ↓ Sell | 133 | $8.62 | $1K | Direct | Sep 6, 2016 (4d) |
| Aug 2, 2016 | GNMK | ↓ Sell | 135 | $9.88 | $1K | Direct | Aug 4, 2016 (2d) |
| Jun 7, 2016 | GNMK | ↓ Sell | 435 | $8.85 | $4K | Direct | Jun 7, 2016 (0d) |
| May 2, 2016 | GNMK | ↓ Sell | 135 | $5.79 | $782 | Direct | May 4, 2016 (2d) |
| Mar 7, 2016 | GNMK | ↓ Sell | 364 | $5.76 | $2K | Direct | Mar 9, 2016 (2d) |
| Mar 2, 2016 | GNMK | ↓ Sell | 1,542 | $4.92 | $8K | Direct | Mar 3, 2016 (1d) |
| Feb 3, 2016 | GNMK | ↓ Sell | 1,916 | $4.99 | $10K | Direct | Feb 5, 2016 (2d) |
| Jan 21, 2016 | GNMK | ↓ Sell | 78 | $6.80 | $530 | Direct | Jan 25, 2016 (4d) |
| Dec 8, 2015 | GNMK | ↓ Sell | 328 | $7.26 | $2K | Direct | Dec 10, 2015 (2d) |
| Dec 3, 2015 | GNMK | ↓ Sell | 1,321 | $7.61 | $10K | Direct | Dec 4, 2015 (1d) |
| Sep 11, 2015 | GNMK | ↓ Sell | 269 | $9.64 | $3K | Direct | Sep 11, 2015 (0d) |
| Sep 4, 2015 | GNMK | ↓ Sell | 1,158 | $9.60 | $11K | Direct | Sep 4, 2015 (0d) |
| Jun 16, 2015 | GNMK | ↓ Sell | 265 | $9.15 | $2K | Direct | Jun 18, 2015 (2d) |
| Jun 4, 2015 | GNMK | ↓ Sell | 1,042 | $9.56 | $10K | Direct | Jun 5, 2015 (1d) |
| Mar 11, 2015 | GNMK | ↓ Sell | 8,658 | $11.94 | $103K | Direct | Mar 11, 2015 (0d) |
| Dec 15, 2014 | GNMK | ↓ Sell | 325 | $12.51 | $4K | Direct | Dec 17, 2014 (2d) |
| Dec 4, 2014 | GNMK | ↓ Sell | 1,320 | $12.06 | $16K | Direct | Dec 8, 2014 (4d) |
| Oct 31, 2014 | GNMK | ↓ Sell | 6,000 | $11.01 | $66K | The Jon Faiz Kayyem and Paige N. Gates F | Oct 31, 2014 (0d) |
| Sep 12, 2014 | GNMK | ↓ Sell | 314 | $9.86 | $3K | Direct | Sep 16, 2014 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other INBX insiders
Open-market trades in the last 12 months
About Jon Faiz Kayyem's insider trades
Jon Faiz Kayyem is a director at Inhibrx Biosciences (INBX). Since Oct 25, 2007, Jon has reported 28 open-market purchases worth $35.2M and 60 sales worth $7.0M on SEC Form 4. In the last 12 months: 3 buys ($1.6M).
Their filings also include grants and awards (25 filings), gifts (7 filings), option exercises (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INBX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.